Long-term findings from the 100-patient QUILT-3.032 cohort show a 71% complete response rate with ANKTIVA plus BCG and 84.2% cystectomy-free survival at three years among responders. The findings strengthen evidence for sustained bladder preservation, although the study was nonrandomized and the preservation estimate does not apply to all treated patients.
EmeraNova has entered a commercialization collaboration involving Hyalomatrix, an established hyaluronic acid-based wound dressing, to expand access across hospitals, wound clinics and surgical settings. The arrangement adds another tissue restoration technology to its portfolio but does not represent a new FDA clearance or acquisition.
The FDA has approved BRYTLY, Alcon's 0.125% apraclonidine eye drops, for temporary relief of redness caused by minor irritation in people aged 12 and older. Alcon claims effects within one minute lasting up to 12 hours, although its longer-duration comparison with Lumify is based on product labeling rather than a disclosed head-to-head trial.
Pelage has dosed the first participant in AWAKEN, a 600-patient Phase 2/3 trial of topical PP405 for male pattern hair loss. The programme follows an exploratory Phase 2a finding in which 31% of selected treated men achieved more than 20% improvement in hair density, compared with none receiving placebo.
Zai Lab will present initial Phase 1 data for ZL-1503 at ACAAI 2026 on November 13, evaluating safety, pharmacokinetics and inflammatory biomarkers in healthy volunteers. The investigational bispecific antibody targets IL-13 and IL-31 receptor signaling, but clinical efficacy in patients with atopic dermatitis remains unreported.
Verastem reports a 50% confirmed response rate in eight second-line pancreatic cancer patients receiving VS-7375, with a 41% rate across 22 previously treated patients at the selected 900 mg dose. The company is preparing a first-line Phase 3 study while pursuing broader development in lung and colorectal cancers.
Pfizer will present 57 infectious disease abstracts at IDWeek 2026, including Phase 3 Lyme vaccine findings, new pediatric pneumococcal data and real-world RSV effectiveness studies. The programme highlights pipeline progress while leaving important regulatory and clinical questions unresolved.
Arrowhead Pharmaceuticals has reported up to 73% mean reduction in cerebrospinal-fluid tau at Day 105 after subcutaneous ARO-MAPT treatment in healthy volunteers. The findings support central nervous system target engagement and a potential quarterly dosing schedule, but cognitive benefit and effects on brain tau pathology remain unproven.
Pilatus Biosciences has dosed its first patient in Hong Kong in the ongoing Phase 1 study of PLT012, an investigational CD36-targeting antibody for advanced cancers. The new hepatocellular carcinoma cohort will examine safety, early clinical activity and biomarkers associated with tumor metabolism and immune suppression.
Ironfist Therapeutics reports that its lutetium-177 Tamrada nanomedicine more than doubled survival when combined with anti-PD-1 therapy in a resistant pancreatic cancer mouse model. The company is preparing a copper-64 imaging study for early 2027, but no human efficacy results are available.